Parametric股票溢價收益主動型ETF PAPI 深 滬
已收盤 05-08 16:00:00 美东时间
26.33
-0.037
-0.14%
華盛通- 最 高26.40
- 今 開26.28
- 成交量 7.52万股
- 最 低 26.245
- 昨 收 26.3673
- 總市值 36.47万
- 52周最高 28.1072
- 市盈率 靜 --
- 換手率 542.64%
- 52周最低 22.8747
- 委 比 0.00%
- 總股本 1.39万
- 歷史最高 27.9783
- 量 比 1.22
- 振 幅 0.59%
- 歷史最低 19.1369
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Immunitybio Announces Nccn® Clinical Practice Guidelines In Oncology Have Been Updated To Include Anktiva® Plus Bcg For Patients With Bcg-Unresponsive Nmibc With Papillary-Only Disease
BRIEF-Immunitybio Announces Nccn® Clinical Practice Guidelines In Oncology Have Been Updated To Include Anktiva® Plus Bcg For Patients With Bcg-Unresponsive Nmibc With Papillary-Only Disease March 17 (Reuters) - Immunitybio Inc IBRX.O : IMMUNITYBIO ANNOUNCES NCCN® CLINICAL PRACTICE GUIDELINES IN ONC
03-17 19:40
BRIEF-SerpApi Files Motion to Dismiss Google's Complaint
BRIEF-SerpApi Files Motion to Dismiss Google's Complaint March 9 (Reuters) - Alphabet Inc GOOGL.O : SERPAPI FILES MOTION TO DISMISS GOOGLE'S COMPLAINT SERPAPI: GOOGLE'S COMPLAINT INVOKES DIGITAL MILLENNIUM COPYRIGHT ACT TO TRY TO STOP SERPAPI FROM ACCESSING ITS WEBSITE Source text: ID:nPnjmDzsa Furt
03-09 19:03
Mainz Biomed To Present Poster Titled BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS At Digestive Disease Week In Chicago
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in
02-24 20:44
Galapagos GLPG posts FY 2025 collaboration revenues of EUR 1.08 billion (+349%)
Galapagos GLPG posts FY 2025 collaboration revenues of EUR 1.08 billion (+349%) Galapagos reported FY 2025 results with total net revenues of EUR 1.11 billion (+304%), including collaboration revenues of EUR 1.08 billion (+349%) and supply revenues of EUR 29.9 million (-14%). Operating profit/loss w
02-24 05:01
BRIEF-SerpApi Files Suit Against SearchApi For "Systematically Stealing" Proprietary Technology
BRIEF-SerpApi Files Suit Against SearchApi For "Systematically Stealing" Proprietary Technology Feb 17 (Reuters) - SerpApi: SERPAPI: FILES SUIT AGAINST SEARCHAPI FOR "SYSTEMATICALLY STEALING" PROPRIETARY TECHNOLOGY Source text: ID:nPn9qB9ypa (( Reuters.Briefs@thomsonreuters.com ;))
02-18 04:16
BRIEF-Google Filed Suit Against SerpApi For Circumventing Security Measures, Protecting Copyrighted Content
Dec 19 (Reuters) - Google: GOOGLE: FILED SUIT AGAINST SERPAPI FOR CIRCUMVENTING SECURITY MEASURES PROTECTING OTHERS' COPYRIGHTED CONTENT THAT APPEARS IN GOOGLE SEARCH RESULTS GOOGLE: FILED SUIT AGAINS...
2025-12-20 02:03
BRIEF-Anktiva® With Bcg Demonstrates 96% Survival From Bladder Cancer
Dec 16 (Reuters) - Immunitybio Inc IBRX.O: ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-...
2025-12-16 22:10
BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis
Oct 13 (Reuters) - Precigen Inc PGEN.O: PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOING DURABLE COMPLETE RESPONSES AFTER TREATMENT WITH PAPZIMEOS, THE FIRST AND ONLY FDA-APPROVED T...
2025-10-13 19:11
BRIEF-Precigen Announces Full FDA Approval Of Papzimeos
Aug 15 (Reuters) - Precigen Inc PGEN.O: PRECIGEN ANNOUNCES FULL FDA APPROVAL OF PAPZIMEOS (ZOPAPOGENE IMADENOVEC-DRBA), THE FIRST AND ONLY APPROVED THERAPY FOR THE TREATMENT OF ADULTS WITH RECURRENT R...
2025-08-15 19:23
BRIEF-Nissan CEO Espinosa - The Consolidation Of Our Manufacturing Footprint Is On Track For Completion By Fiscal Year 2027
July 30 (Reuters) - Nissan Motor Co Ltd 7201.T: NISSAN CEO ESPINOSA: THE CONSOLIDATION OF OUR MANUFACTURING FOOTPRINT IS ON TRACK FOR COMPLETION BY FISCAL YEAR 2027 NISSAN CFO PAPIN: WE MAINTAIN AMPLE...
2025-07-30 16:17
